Empower is utilizing clinics, physicians, technology and direct access to 165,000 patients to launch dedicated division and resources for psilocybin research.
VANCOUVER, BC / ACCESSWIRE / April 22, 2020 / EMPOWER CLINICS INC. (CSE: CBDT)(OTC: EPWCF)(Frankfurt 8EC) (“Empower” or the “Company”), a vertically integrated and growth-oriented life sciences company is pleased to announce, it is has created a subsidiary company dedicated to the advancement of psilocybin research and patient care, addressing the significant mental health issues of anxiety, depression, post-traumatic stress disorder (PTSD) and addiction.
The Company is leveraging its assets that include the existing clinic network, the developing franchise brand, tele-medicine, access to its 165,000 patients and large physician team, to make advancements in psilocybin research and psychedelics therapy in general.
“Mental health conditions such as anxiety, depression, addiction and PTSD appear to be on the rise with the onset of the Coronavirus pandemic.” said Steven McAuley, Chairman & CEO of Empower. “Clinical trials continue to show that psilocybin therapies may provide tremendous help with these conditions, that we see every day in our clinics. As a Company, we must endeavour to utilize our assets and capabilities to positively impact patients’ lives.”
The mental health crisis could cost the world $16 trillion by 2030 according to Future Market Insights and further, the global behavioral health (non-pharmacological) market is expected to be valued at US$156 billion by 2028.
According to the World Health Organization (WHO), depression is the leading cause of disability worldwide, and it is a major contributor to the overall global burden of disease.
The United States Food and Drug Administration has determined that preliminary clinical evidence indicates psilocybin may demonstrate substantial improvement over other available therapies for treatment-resistant depression; and granted a Breakthrough Therapy designation for a treatment that uses psilocybin as a therapy for such depression.
Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.
ON BEHALF OF THE BOARD OF DIRECTORS:
Chief Executive Officer
Investors: Steven McAuley
Investors: Dustin Klein
SVP, Business Development
For French inquiries: Remy Scalabrini, Maricom Inc., E: firstname.lastname@example.org, T: (888) 585-MARI
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
SOURCE: Empower Clinics Inc.
View source version on accesswire.com: